EarlyCDT®Lung measures autoantibodies to detect lung cancer

  • EarlyCDT-Lung measures blood levels of seven autoantibodies produced in response to lung cancer tumor associated antigens (TAA’s)
  • These autoantibodies can be at elevated levels in the blood from the earliest stages of lung cancer. They have been shown to be elevated for all types of lung cancer, and at all stages of the disease
  • EarlyCDT-Lung can detect elevated levels of autoantibodies up to four years earlier than when the tutor is first visible on CT scan2
  • Early diagnosis of lung cancer significantly improves the chances of survival3

Oncimmune’s patented EarlyCDT® autoantibody technology can be applied to many solid tumor types

  • Oncimmune has 9 patent families that protect the products and its intellectual property. This has led to numerous granted patents in 50 countries worldwide. There are specific patents that cover the EarlyCDT-Lung test, prohibiting competitors from marketing identical diagnostics tests. Oncimmune is continually monitoring the IP landscape, and further patent applications are in the pipeline
  • Oncimmune will launch EarlyCDT® for Liver cancer in Q1 2018
  • We are also working on tests for ovarian and breast cancer

1 Lam S, et al. EarlyCDT-Lung: an Immuno-biomarker Test as an Aid to Early Detection of Lung Cancer. Cancer Prev Res 2011; 4(7); 1126–34
Chapman CJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol. 2012;33(5):1319-26
2 Zhong L, et al., Profiling Tumour-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer. J Thor Oncol 2006; 1:513-519
Jett J, et al., Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. J Thor Oncol 2017; 12(11):S2170
3 The National Lung Screening Trial Research Team.  N Engl J Med 2011; 365:395-409


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept